Literature DB >> 8246549

Atrioventricular valve competence after takedown to improve exposure during ventricular septal defect repair.

A K Pridjian1, F B Pearce, W S Culpepper, L C Williams, C H Van Meter, J L Ochsner.   

Abstract

Although the atrioventricular valve and its attachments can sometimes obscure the superior margin of a ventricular septal defect, concern for valvular competence has made surgeons hesitant to take down the atrioventricular valve. Over a 10-year period, the right atrioventricular valve was taken down to improve exposure for ventricular septal defect repair in 40 patients at our institution, and follow-up echocardiographic studies to determine the degree of valvular regurgitation were available in 32. On the basis of the area of the color flow jet, valvular regurgitation was graded as none in 22 and trivial in 10. Heart block did not develop in any patient, and there were no deaths. Takedown and resuspension of the atrioventricular valve is a safe and effective technique that improves exposure for ventricular septal defect repair and does not adversely affect valve competence.

Entities:  

Mesh:

Year:  1993        PMID: 8246549

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Tricuspid valve detachment in closure of congenital ventricular septal defect.

Authors:  Jinping Zhao; Jun Li; Xiang Wei; Bo Zhao; Wei Sun
Journal:  Tex Heart Inst J       Date:  2003

2.  Novel method for evaluating tricuspid valve function after tricuspid valve detachment in the repair of perimembranous ventricular septal defects.

Authors:  Ying-Jui Lin; Jen-Ping Chang; Shao-Ju Chien; Chi-Di Liang; Chien-Fu Huang; Chiung-Lun Kao
Journal:  Tex Heart Inst J       Date:  2012

3.  Outcomes of Tricuspid Valve Detachment for Isolated Ventricular Septal Defect Closure.

Authors:  John Schittek; Jörg S Sachweh; Florian Arndt; Maria Grafmann; Ida Hüners; Rainer Kozlik-Feldmann; Daniel Biermann
Journal:  Thorac Cardiovasc Surg       Date:  2021-11-10       Impact factor: 1.827

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.